scholarly journals Models of breast cancer: is merging human and animal models the future?

2003 ◽  
Vol 6 (1) ◽  
Author(s):  
Jong B Kim ◽  
Michael J O'Hare ◽  
Robert Stein
Keyword(s):  
Breast Cancer ◽  
Animal Models ◽  
The Future

scholarly journals New insights on CRISPR/Cas9-based therapy for breast Cancer

2021 ◽  
Vol 43 (1) ◽  
Author(s):  
Hussein Sabit ◽  
Shaimaa Abdel-Ghany ◽  
Huseyin Tombuloglu ◽  
Emre Cevik ◽  
Amany Alqosaibi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Animal Models ◽  
Human Cancer ◽  
Step Process ◽  
Cancer Initiation ◽  
Malignant State ◽  
Treat Breast Cancer

AbstractCRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems.

scholarly journals G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

2020 ◽  
Vol 180 (3) ◽  
pp. 635-646 ◽  
Author(s):  
Kaitlyn J. Andreano ◽  
Suzanne E. Wardell ◽  
Jennifer G. Baker ◽  
Taylor K. Desautels ◽  
Robert Baldi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Animal Models ◽  
Tumor Growth ◽  
Inhibit Tumor Growth

Dose-dense chemotherapy for breast cancer: what does the future hold?

2010 ◽  
Vol 6 (6) ◽  
pp. 951-965 ◽  
Author(s):  
Patrick G Morris ◽  
Heather L McArthur ◽  
Clifford Hudis ◽  
Larry Norton
Keyword(s):  
Breast Cancer ◽  
The Future ◽  
Dose Dense

Breast Cancer: Reviewing the Past to Give Direction for the Future

2013 ◽  
Vol 40 (5) ◽  
pp. 425-428 ◽  
Author(s):  
Diane G. Cope
Keyword(s):  
Breast Cancer ◽  
The Past ◽  
The Future

scholarly journals Automated computer quantification of breast cancer in small-animal models using PET-guided MR image co-segmentation

2013 ◽  
Vol 3 (1) ◽  
pp. 49 ◽  
Author(s):  
Ulas Bagci ◽  
Gabriela Kramer-Marek ◽  
Daniel J Mollura
Keyword(s):  
Breast Cancer ◽  
Animal Models ◽  
Small Animal ◽  
Mr Image ◽  
Small Animal Models

scholarly journals ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes

Cells ◽  
2018 ◽  
Vol 7 (12) ◽  
pp. 248 ◽  
Author(s):  
Aurore Claude-Taupin ◽  
Leïla Fonderflick ◽  
Thierry Gauthier ◽  
Laura Mansi ◽  
Jean-René Pallandre ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cancer Cell Line ◽  
Cancer Tissue ◽  
The Future ◽  
Cancer Phenotypes

Early detection and targeted treatments have led to a significant decrease in mortality linked to breast cancer (BC), however, important issues need to be addressed in the future. One of them will be to find new triple negative breast cancer (TNBC) therapeutic strategies, since none are currently efficiently targeting this subtype of BC. Since numerous studies have reported the possibility of targeting the autophagy pathway to treat or limit cancer progression, we analyzed the expression of six autophagy genes (ATG9A, ATG9B, BECLIN1, LC3B, NIX and P62/SQSTM1) in breast cancer tissue, and compared their expression with healthy adjacent tissue. In our study, we observed an increase in ATG9A mRNA expression in TNBC samples from our breast cancer cohort. We also showed that this increase of the transcript was confirmed at the protein level on paraffin-embedded tissues. To corroborate these in vivo data, we designed shRNA- and CRISPR/Cas9-driven inhibition of ATG9A expression in the triple negative breast cancer cell line MDA-MB-436, in order to determine its role in the regulation of cancer phenotypes. We found that ATG9A inhibition led to an inhibition of in vitro cancer features, suggesting that ATG9A can be considered as a new marker of TNBC and might be considered in the future as a target to develop new specific TNBC therapies.

scholarly journals What is the future in the treatment of triple-negative breast cancer?

2017 ◽  
Vol 3 (3) ◽  
pp. 147
Author(s):  
Erdinc Nayir ◽  
Tolga Koseci
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
The Future

The Future of Radiation Therapy for Breast Cancer

2009 ◽  
Vol 20 (2) ◽  
pp. 128-131
Author(s):  
Meena S. Moran
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
The Future
Sign in / Sign up

Export Citation Format

Share Document